Michael J. Mcbreen Receives Stock Award at Integra Lifesciences Holdings Corp (IART) — SEC Form 4, Feb 14, 2022

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Michael J. Mcbreen

EVP

TXN 2022-02-11 · FILED 2022-02-14

Equity Position 19.7K sh 9,737 → 19,727

Equity Change +102.6% shares held after vs before

Filing Lag 1 business day within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Integra Lifesciences Holdings Corp

IART CIK 0000917520

Reporting Owner

Name	Relationship
Michael J. Mcbreen CIK 0001814943	EVP

Michael J. Mcbreen at Integra Lifesciences Holdings Corp Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at Integra Lifesciences Holdings Corp

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1	2022-02-11	A - Award/Grant	1,458 A	$0.00	—	11,195	Direct
Common StockF2	2022-02-11	A - Award/Grant	2,424 A	$0.00	—	13,619	Direct
Common StockF3	2022-02-11	A - Award/Grant	6,108 A	$0.00	—	19,727	Direct

Footnotes (3)

F1: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 13, 2019 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 34% of the shares will vest on March 13, 2022 at 150% of target, the third anniversary of the grant date. Show more
F2: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 13, 2020 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2022 at 150% of target, the second anniversary of the grant date. Show more
F3: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 12, 2021 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 12, 2022 at 200% of target, the first anniversary of the grant date. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 3 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Integra Lifesciences Holdings Corp

GET /v1/forms/4/0001209191-22-009350 API docs